Correlative Analysis Of CXCR6 Expression And Efficacy Of Immunocheckpoint Inhibitors In Advanced NSCLC

Objective(s): To explore the correlation between the expression of CXCR6 in tissues of patients with advanced NSCLC and the efficacy of immunotherapy.To provide a theoretical basis for exploring new therapeutic efficacy prediction indicators for NSCLC immunotherapy.Methods: Collect clinical data and tissue sections of advanced NSCLC patients who visited the Oncology Department of Yunnan First People’s Hospital from January2019 to June 30,2022 and received Immune Checkpoint Inhibitors(ICIs)(ICIs monotherapy,ICIs combined chemotherapy,ICIs combined targeted therapy,and dual ICIs)for at least 4 cycles.General clinical data,including gender,age,pathological type,number of immunotherapy lines and medication methods,peripheral blood routine,T lymphocyte subsets,etc.Immunohistochemical methods were used to detect the expression level of CXC chemokine receptor 6(CXCR6)in tumor tissue of patients before treatment.According to the immunohistochemical results of CXCR6,patients were divided into high expression group and low expression group/negative group.Differences between the two groups were analyzed through chi square test,independent sample T test,and non parametric test;Exploring the correlation between Kaplan-Meier survival analysis and COX regression model and the prognosis of ICIs treatment.Results: 1.The single factor Kaplan Meier results show that: the average survival time of patients with low/negative CXCR6 expression in tissues of stage III-IV NSCLC patients receiving ICIs treatment was 5.53 months,the median PFS time was6.00 months,and the cumulative survival rate at 6 months was 60.50%;The average survival time of high expression patients was 14.52 months,with a median PFS time of 10.37 months.The survival analysis results of the multivariate COX proportional risk model suggest that the expression level of CXCR6 in tissues of advanced NSCLC patients is a protective factor affecting ICIs treatment [HR=1.425,95%CI(1.039,16.634),(P<0.05)].The higher the expression level of CXCR6,the lower the risk of disease progression.The expression level of CXCR6 is a protective factor affecting ICIs treatment in NSCLC patients.The higher the expression level of CXCR6,the lower the risk of disease progression.2.The expression level of CXCR6 in tissues of advanced NSCLC patients receiving ICIs treatment is positively correlated with the amount of hemoglobin in peripheral blood,and negatively correlated with platelet count/lymphocyte count.Conclusion(s): The expression level of CXCR6 in tissues of advanced non-small cell lung cancer patients has a certain predictive effect on the prognosis of patients receiving ICIs treatment,and is a potential biomarker for the prognosis of ICIs treatment.In addition,the combination of immune indicators and peripheral blood inflammation indicators can dynamically monitor the patient’s immune ability to a certain extent,providing a certain indicator for the patient’s anti-tumor immunity.